Purpose: Transarterial chemoembolization (TACE) in combination with stereotactic body radiation therapy (SBRT) is a promising therapy for patients with hepatocellular carcinoma (HCC). A radiopaque drug-eluting embolic bead used during TACE, called LC Bead LUMI (Boston Scientific), was developed to allow improved visualization during TACE. The purpose of this case series is to assess the visibility of LUMI after TACE and discuss its potential use as an alignment tool for SBRT.
Methods: Fourteen patients with HCC (median age 69) received TACE using LUMI immediately followed by SBRT to 50 Gy in 5 fractions (13 patients) or 40 Gy in 5 fractions (1). Computed tomography (CT) simulation and cone beam CT (CBCT) images taken before each fraction were compared with immediate post-TACE imaging. Success of the LUMI bead opacification was graded from excellent to poor visualization. Patients were followed to assess target lesion response, disease control, survival, and the long-term visibility of LUMI beads.
Results: CBCT immediately after TACE with LUMI displayed excellent tumor visibility for 6 of 13 patients (46.2%), moderate tumor visibility for 4 patients (30.8%), and poor tumor visibility for 3 patients (23.1%). When comparing CBCTs used for SBRT image verification to post-TACE CBCT, 53.8% remained unchanged and 46.2% deteriorated from excellent to moderate or moderate to poor, but none deteriorated from excellent to poor visualization. Median follow-up was 13 months (range 2-35). On average, LUMI beads were visible on noncontrast CT up to 20 months after SBRT.
Conclusions: LC Bead LUMI has the ability to provide liver tumor demarcation on noncontrast and cone beam CT weeks to months following TACE. It can serve as an alignment tool and could improve the therapeutic ratio in liver SBRT by allowing for tumor margin reduction with a potential decrease in the risk of toxicity when treating HCC in facilities without magnetic resonance imaging-linear accelerator.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8767242 | PMC |
| http://dx.doi.org/10.1016/j.adro.2021.100830 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Performance and Safety of a Reflux-Control Microcatheter Used to Perform DEB-TACE with LUMI Beads in HCC Patients: Preliminary Experience.
J Clin Med
October 2023
Department of Diagnostic and Interventional Radiology, Foundation IRCCS Cà Granda-Ospedale Maggiore Policlinico, Via Francesco Sforza 35, 20122 Milan, Italy.
Article Synopsis
- The study investigates the use of an anti-reflux microcatheter during a treatment called DEB-TACE with DC Bead LUMI for patients with hepatocellular carcinoma (HCC).
- The results showed that the treatment was technically successful for all patients, but 55% had some residual disease after the procedure; over 45% showed no disease over a one-month follow-up.
- Safety was confirmed as there were no major complications, minor complications occurred in 10% of cases, and a high percentage of the tumor was covered by the beads in most cases (70%).
Efficacy and Safety of Transarterial Chemoembolization with DC Beads LUMI in the Treatment of HCC: Experience from a Tertiary Centre.
Technol Cancer Res Treat
November 2023
Diagnostic and Interventional Radiology Department, IRCCS Cà Granda Fondazione Ospedale Maggiore Policlinico, Università degli Studi di Milano, Milan, Italy.
Purpose: The aim of this study was to describe the safety and efficacy profiles of TACE using DC Beads LUMI.
Materials And Methods: We retrospectively analyzed 90 patients with HCC who underwent TACE with DC Bead LUMI™ between November 2018 and November 2020 at Fondazione IRCCS Cà Granda Policlinico Hospital in Milan, Italy. Patient- and tumour-related factors were registered, including the number of treated lesions, dose of DC Beads LUMI™, dose of Epirubicin, DC Beads LUMI™ target tumour coverage (LC) according to the percentage of target nodule involvement (LC1-0%-25%, LC2-25%-50%, LC3-50%-75%, LC4 75%-100%).
Safety, Efficacy and Distribution of Doxorubicin Loaded Radiopaque Beads in Chemoembolization in Intermediate Stage Hepatocellular Carcinoma (HCC) with Correlation with Local Response.
Cardiovasc Intervent Radiol
March 2023
2nd Department of Radiology, School of Medicine, Attikon University Hospitals, National and Kapodistrian University of Athens, Katerina Malagari, 19 Monis Kyccou, 15 669, Papagou, Athens, Greece.
Purpose: The primary objectives of this study were to evaluate safety, and efficacy of Transarterial Chemoembolization (TACE) using doxorubicin-loaded radiopaque microspheres (DC Bead LUMI™) for the treatment of early and intermediate stage Hepatocellular Carcinoma (HCC) not amenable for curative treatments. Distribution of the microspheres was correlated with results post embolization.
Materials And Methods: This was a prospective, single arm, open label study.
In vitro characterization of immune modulating drug-eluting immunobeads towards transarterial embolization in cancer.
Sci Rep
December 2022
Center for Interventional Oncology, Radiology and Imaging Sciences, NIH Clinical Center, National Institutes of Health, Bethesda, MD, USA.
Article Synopsis
- Hepatocellular carcinoma (HCC) is a serious type of liver cancer, and researchers are looking for better treatment options.
- In this study, scientists tested different drugs loaded into special beads to see how much medicine they could hold and how fast it could be released.
- They found that some drugs released quickly while others took longer, and the results could help in developing new ways to treat HCC more effectively.
Impact of Chemoembolic Regimen on Immune Cell Recruitment and Immune Checkpoint Marker Expression following Transcatheter Arterial Chemoembolization in a VX2 Rabbit Liver Tumor Model.
J Vasc Interv Radiol
July 2022
Department of Radiology and Biomedical Imaging, Yale School of Medicine, New Haven, Connecticut. Electronic address:
Purpose: To characterize the effects of commonly used transcatheter arterial chemoembolization (TACE) regimens on the immune response and immune checkpoint marker expression using a VX2 rabbit liver tumor model.
Materials And Methods: Twenty-four VX2 liver tumor-bearing New Zealand white rabbits were assigned to 7 groups (n = 3 per group) undergoing locoregional therapy as follows: (a) bicarbonate infusion without embolization, (b) conventional TACE (cTACE) using a water-in-oil emulsion containing doxorubicin mixed 1:2 with Lipiodol, drug-eluting embolic-TACE with either (c) idarubicin-eluting Oncozene microspheres (40 μm) or (d) doxorubicin-eluting Lumi beads (40-90 μm). For each therapy arm (b-d), a tandem set of 3 animals with additional bicarbonate infusion before TACE was added, to evaluate the effect of pH modification on the immune response.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!